primaryid int64 82.9M 2.23B | caseid int64 8.29M 23.4M | caseversion int64 1 47 | i_f_code stringclasses 2
values | event_dt float64 20M 20.2M ⌀ | mfr_dt float64 20.2M 20.2M ⌀ | init_fda_dt stringdate 2011-12-14 00:00:00 2023-12-31 00:00:00 | fda_dt stringdate 2023-01-02 00:00:00 2023-12-31 00:00:00 | rept_cod stringclasses 5
values | auth_num stringclasses 98
values | mfr_num stringlengths 13 54 ⌀ | mfr_sndr stringclasses 138
values | lit_ref stringclasses 81
values | age float64 0 24.3k ⌀ | age_cod stringclasses 4
values | age_grp stringclasses 6
values | sex stringclasses 3
values | e_sub stringclasses 2
values | wt float64 2 245 ⌀ | wt_cod stringclasses 2
values | rept_dt stringdate 2022-12-21 00:00:00 2023-12-31 00:00:00 | to_mfr stringclasses 2
values | occp_cod stringclasses 5
values | reporter_country stringclasses 48
values | occr_country stringclasses 46
values | _quarter stringclasses 4
values | age_years float64 0 95 ⌀ | sex_label stringclasses 3
values | reporter_type stringclasses 5
values | report_type stringclasses 5
values | wt_kg float64 2 175 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
228,574,972 | 22,857,497 | 2 | F | null | 20,230,817 | 2023-08-23 | 2023-11-17 | PER | null | US-Stemline Therapeutics, Inc.-2023ST001281 | STEMLINE THERAPEUTICS | null | 46 | YR | A | F | Y | null | null | 2023-11-16 | null | CN | US | US | 2023Q4 | 46 | Female | Consumer | Periodic | null |
227,902,501 | 22,790,250 | 1 | I | 20,230,726 | 20,230,802 | 2023-08-05 | 2023-08-05 | PER | null | US-AMGEN-USASP2023137299 | AMGEN | null | 75 | YR | E | F | Y | null | null | 2023-08-05 | null | PH | US | US | 2023Q3 | 75 | Female | Pharmacist | Periodic | null |
218,474,441 | 21,847,444 | 1 | I | null | 20,230,106 | 2023-01-11 | 2023-01-11 | PER | null | US-SA-2023SA010030 | SANOFI AVENTIS | null | null | null | C | M | Y | null | null | 2023-01-11 | null | MD | US | US | 2023Q1 | null | Male | Physician | Periodic | null |
229,420,331 | 22,942,033 | 1 | I | null | 20,230,912 | 2023-09-14 | 2023-09-14 | PER | null | US-ELI_LILLY_AND_COMPANY-US202309007169 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 2023-09-14 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Periodic | null |
228,820,692 | 22,882,069 | 2 | F | 20,210,101 | 20,230,905 | 2023-08-30 | 2023-09-08 | EXP | null | NVSC2023MX186837 | NOVARTIS | null | null | null | null | F | Y | 45 | KG | 2023-09-08 | null | CN | MX | MX | 2023Q3 | null | Female | Consumer | Expedited | 45 |
192,474,482 | 19,247,448 | 2 | F | 20,200,505 | 20,200,505 | 2021-05-12 | 2023-05-29 | PER | null | US-UCBSA-2020018706 | UCB | null | 48 | YR | null | F | Y | null | null | 2023-05-29 | null | HP | US | US | 2023Q2 | 48 | Female | Health professional | Periodic | null |
216,123,003 | 21,612,300 | 3 | F | 20,221,111 | 20,230,109 | 2022-11-18 | 2023-01-16 | PER | null | US-AMGEN-USASP2022197060 | AMGEN | null | null | null | null | null | Y | null | null | 2023-01-16 | null | HP | US | US | 2023Q1 | null | Unknown | Health professional | Periodic | null |
231,679,301 | 23,167,930 | 1 | I | null | 20,231,108 | 2023-11-09 | 2023-11-09 | EXP | null | ES-GILEAD-2023-0650482 | GILEAD | null | 64 | YR | A | null | Y | null | null | 2023-11-09 | null | HP | ES | ES | 2023Q4 | 64 | Unknown | Health professional | Expedited | null |
227,833,451 | 22,783,345 | 1 | I | null | 20,230,727 | 2023-08-03 | 2023-08-03 | EXP | null | US-ABBVIE-5353235 | ABBVIE | Ailawadhi S, Paulus A, Laplant B, Alegria V, Zimmerman A, Chapin D, Sher T, Roy V, Chanan-Khan A, Parrondo R. Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 2022;140 (SUPPLEMENT 1)... | null | null | null | null | Y | null | null | 2023-08-03 | null | HP | US | US | 2023Q3 | null | Unknown | Health professional | Expedited | null |
228,592,032 | 22,859,203 | 2 | F | 20,230,721 | 20,231,121 | 2023-08-24 | 2023-11-24 | EXP | null | US-JNJFOC-20230841310 | JOHNSON AND JOHNSON | null | 41 | YR | A | F | Y | null | null | 2023-11-24 | null | MD | US | US | 2023Q4 | 41 | Female | Physician | Expedited | null |
225,361,791 | 22,536,179 | 1 | I | null | null | 2023-06-07 | 2023-06-07 | DIR | FDA-CDER-CTU-2023-42197 | null | FDA-CTU | null | null | null | null | M | N | null | null | 2023-06-07 | N | null | US | null | 2023Q2 | null | Male | null | Direct | null |
229,689,661 | 22,968,966 | 1 | I | 20,030,101 | 20,230,911 | 2023-09-22 | 2023-09-22 | EXP | DE-002147023-NVSC2023DE192251 | DE-PBT-008307 | PANACEA BIOTEC | null | 28 | YR | A | M | Y | null | null | 2023-09-22 | null | MD | DE | DE | 2023Q3 | 28 | Male | Physician | Expedited | null |
204,721,912 | 20,472,191 | 2 | F | 20,220,112 | 20,230,521 | 2022-02-14 | 2023-06-01 | EXP | null | JP-SUNPHARMA-2022R1-325972AA | RANBAXY | null | 73 | YR | null | F | Y | 47 | KG | 2023-06-01 | null | MD | JP | JP | 2023Q2 | 73 | Female | Physician | Expedited | 47 |
228,390,801 | 22,839,080 | 1 | I | null | 20,230,817 | 2023-08-18 | 2023-08-18 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-116449 | BRISTOL MYERS SQUIBB | null | 61 | YR | A | F | Y | null | null | 2023-08-18 | null | HP | US | US | 2023Q3 | 61 | Female | Health professional | Periodic | null |
219,934,451 | 21,993,445 | 1 | I | 20,221,206 | 20,230,214 | 2023-02-15 | 2023-02-15 | EXP | SE-MPA-2023-001015 | SE-BRISTOL-MYERS SQUIBB COMPANY-2023-021935 | BRISTOL MYERS SQUIBB | null | 72 | YR | E | M | Y | null | null | 2023-02-15 | null | MD | SE | SE | 2023Q1 | 72 | Male | Physician | Expedited | null |
229,710,631 | 22,971,063 | 1 | I | null | 20,230,914 | 2023-09-22 | 2023-09-22 | PER | null | US-MYLANLABS-2023M1100641 | MYLAN | null | null | null | null | null | Y | null | null | 2023-09-22 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Periodic | null |
184,224,784 | 18,422,478 | 4 | F | 20,230,101 | 20,230,512 | 2020-10-23 | 2023-05-26 | EXP | null | US-TEVA-2020-US-1841509 | TEVA | null | null | null | null | F | Y | null | null | 2023-05-26 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Expedited | null |
218,951,381 | 21,895,138 | 1 | I | null | 20,230,109 | 2023-01-22 | 2023-01-22 | EXP | null | TH-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-373700 | RANBAXY | Thumtecho S, Sriworasuwat P, Wainipitapong S. Suicidal attempts and self-poisoning: 1-year retrospective cohort study from the quaternary hospital in Thai metropolitan area. Health Sci Rep. 2022;5(6):e941 | 66 | YR | null | F | Y | null | null | 2023-01-23 | null | HP | TH | TH | 2023Q1 | 66 | Female | Health professional | Expedited | null |
223,343,731 | 22,334,373 | 1 | I | 20,230,515 | 20,230,516 | 2023-05-17 | 2023-05-17 | EXP | null | US-AstraZeneca-2023A114269 | ASTRAZENECA | null | 24,260 | DY | null | M | Y | null | null | 2023-05-18 | null | CN | US | null | 2023Q2 | 66.42 | Male | Consumer | Expedited | null |
221,015,691 | 22,101,569 | 1 | I | 20,230,220 | 20,230,314 | 2023-03-16 | 2023-03-16 | EXP | null | GB-BRISTOL-MYERS SQUIBB COMPANY-2023-037934 | BRISTOL MYERS SQUIBB | null | 83 | YR | E | F | Y | null | null | 2023-03-16 | null | CN | GB | US | 2023Q1 | 83 | Female | Consumer | Expedited | null |
93,558,383 | 9,355,838 | 3 | F | 20,121,005 | 20,230,808 | 2013-06-19 | 2023-08-14 | PER | null | JP-NAPPMUNDI-GBR-2013-0014576 | PURDUE | null | 71 | YR | null | F | Y | 42 | KG | 2023-08-14 | null | MD | JP | JP | 2023Q3 | 71 | Female | Physician | Periodic | 42 |
226,025,171 | 22,602,517 | 1 | I | null | 20,230,609 | 2023-06-14 | 2023-06-14 | EXP | null | US-BIOGEN-2023BI01210326 | BIOGEN | null | null | null | null | F | Y | null | null | 2023-06-14 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Expedited | null |
231,196,631 | 23,119,663 | 1 | I | null | 20,230,712 | 2023-10-29 | 2023-10-29 | EXP | null | US-ENDO-CASE-0036102 | ENDO | null | null | null | null | M | Y | null | null | 2023-10-28 | null | CN | US | null | 2023Q4 | null | Male | Consumer | Expedited | null |
229,952,481 | 22,995,248 | 1 | I | null | 20,230,712 | 2023-09-27 | 2023-09-27 | EXP | null | US-ENDO-CASE-0020373 | ENDO | null | null | null | null | F | Y | null | null | 2023-09-27 | null | CN | US | null | 2023Q3 | null | Female | Consumer | Expedited | null |
226,887,812 | 22,688,781 | 2 | F | 20,230,614 | 20,230,721 | 2023-07-10 | 2023-07-26 | EXP | null | US-Calliditas-2023CAL00823 | CALLIDITAS THERAPEUTICS | null | 55 | YR | A | M | Y | null | null | 2023-07-26 | null | CN | US | US | 2023Q3 | 55 | Male | Consumer | Expedited | null |
223,412,881 | 22,341,288 | 1 | I | null | 20,230,507 | 2023-05-18 | 2023-05-18 | EXP | null | GB-Canton Laboratories, LLC-2141689 | CANTON LABORATORIES | null | null | null | null | null | Y | null | null | 2023-05-18 | null | null | GB | GB | 2023Q2 | null | Unknown | null | Expedited | null |
219,672,331 | 21,967,233 | 1 | I | 20,180,101 | 20,230,206 | 2023-02-08 | 2023-02-08 | EXP | null | NVSC2023US027401 | NOVARTIS | null | null | null | null | null | Y | null | null | 2023-02-08 | null | LW | US | US | 2023Q1 | null | Unknown | Lawyer | Expedited | null |
231,547,741 | 23,154,774 | 1 | I | null | 20,231,027 | 2023-11-07 | 2023-11-07 | EXP | null | IE-Ascend Therapeutics US, LLC-2147786 | ASCEND | null | null | null | null | F | Y | null | null | 2023-11-07 | null | HP | IE | IE | 2023Q4 | null | Female | Health professional | Expedited | null |
233,267,521 | 23,326,752 | 1 | I | 20,231,218 | 20,231,219 | 2023-12-21 | 2023-12-21 | PER | null | US-AMGEN-USASP2023227761 | AMGEN | null | null | null | null | F | Y | null | null | 2023-12-21 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Periodic | null |
227,981,981 | 22,798,198 | 1 | I | 20,230,101 | 20,230,309 | 2023-08-08 | 2023-08-08 | 5DAY | null | US-REGENERON PHARMACEUTICALS, INC.-2023-038995 | REGENERON | null | null | null | null | F | Y | null | null | 2023-08-08 | null | MD | US | US | 2023Q3 | null | Female | Physician | 5DAY | null |
227,146,041 | 22,714,604 | 1 | I | 20,230,710 | 20,230,713 | 2023-07-18 | 2023-07-18 | PER | null | US-ELI_LILLY_AND_COMPANY-US202307007948 | ELI LILLY AND CO | null | 59 | YR | null | M | Y | null | null | 2023-07-18 | null | CN | US | US | 2023Q3 | 59 | Male | Consumer | Periodic | null |
232,186,722 | 23,218,672 | 2 | F | null | 20,231,117 | 2023-11-22 | 2023-11-24 | EXP | null | JP-AstraZeneca-2023A262025 | ASTRAZENECA | null | null | null | null | null | Y | null | null | 2023-11-24 | null | PH | JP | null | 2023Q4 | null | Unknown | Pharmacist | Expedited | null |
231,533,411 | 23,153,341 | 1 | I | null | 20,231,030 | 2023-11-07 | 2023-11-07 | EXP | null | US-MYLANLABS-2023M1117564 | MYLAN | Hunley TE, Hidalgo G, Ng KH, Shirai Y, Miura K, Beng HM, et al. Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. Pediatr-Nephrol 2023;38(4):1127-1138. | 13 | YR | null | F | Y | null | null | 2023-11-07 | null | HP | US | US | 2023Q4 | 13 | Female | Health professional | Expedited | null |
229,917,951 | 22,991,795 | 1 | I | null | 20,230,612 | 2023-09-27 | 2023-09-27 | PER | null | US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-23-02098 | HIKMA | null | null | null | null | null | Y | null | null | 2023-09-27 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Periodic | null |
229,772,061 | 22,977,206 | 1 | I | 20,230,909 | 20,230,911 | 2023-09-25 | 2023-09-25 | PER | null | US-JNJFOC-20230926313 | JOHNSON AND JOHNSON | null | 76 | YR | E | F | Y | null | null | 2023-09-25 | null | CN | US | US | 2023Q3 | 76 | Female | Consumer | Periodic | null |
229,600,412 | 22,960,041 | 2 | F | 20,230,101 | 20,231,106 | 2023-09-20 | 2023-11-10 | EXP | null | US-UCBSA-2023042917 | UCB | null | null | null | null | M | Y | null | null | 2023-11-10 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Expedited | null |
223,798,891 | 22,379,889 | 1 | I | null | 20,230,516 | 2023-05-29 | 2023-05-29 | EXP | null | CA-HLS-202301173 | HLS THERAPEUTICS | null | 23 | YR | A | F | Y | null | null | 2023-05-29 | null | HP | CA | CA | 2023Q2 | 23 | Female | Health professional | Expedited | null |
227,104,721 | 22,710,472 | 1 | I | null | 20,230,703 | 2023-07-17 | 2023-07-17 | PER | null | US-GALDERMA-US2023010306 | GALDERMA | null | null | null | null | null | Y | null | null | 2023-07-17 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Periodic | null |
232,823,922 | 23,282,392 | 2 | F | null | 20,231,213 | 2023-12-11 | 2023-12-15 | EXP | null | NVSC2023IN260702 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-12-15 | null | CN | IN | IN | 2023Q4 | null | Female | Consumer | Expedited | null |
220,244,691 | 22,024,469 | 1 | I | 20,220,311 | 20,220,314 | 2023-02-23 | 2023-02-23 | EXP | null | US-ROCHE-3051514 | ROCHE | null | null | null | null | null | Y | null | null | 2023-02-23 | null | HP | US | null | 2023Q1 | null | Unknown | Health professional | Expedited | null |
229,495,851 | 22,949,585 | 1 | I | null | 20,230,911 | 2023-09-15 | 2023-09-15 | EXP | null | US-SANDOZ INC.-SDZ2023US028795 | SANDOZ | null | null | null | null | F | Y | 57.596 | KG | 2023-09-15 | null | MD | US | US | 2023Q3 | null | Female | Physician | Expedited | 57.6 |
231,804,092 | 23,180,409 | 2 | F | 20,230,101 | 20,231,128 | 2023-11-14 | 2023-12-06 | EXP | null | PL-BAXTER-2023BAX035382 | BAXTER | Wojcik Superczynska M..Long-term response during immunochemotherapy in a female patient with lung adenocarcinoma showing lesions of the type of oligoprogression treated with radiotherapy.Oncology in Clinical Practice - Education 2023;9 Suppl.B:B73-B77. | 52 | YR | null | F | Y | null | null | 2023-12-06 | null | MD | PL | PL | 2023Q4 | 52 | Female | Physician | Expedited | null |
230,200,323 | 23,020,032 | 3 | F | 20,230,101 | 20,231,130 | 2023-10-03 | 2023-12-06 | EXP | null | US-UCBSA-2023047295 | UCB | null | null | null | null | F | Y | null | null | 2023-12-06 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Expedited | null |
221,155,671 | 22,115,567 | 1 | I | 20,201,217 | 20,230,308 | 2023-03-20 | 2023-03-20 | EXP | SE-MPA-2022-011063 | SE-BAYER-2023A030931 | BAYER | null | 27 | YR | A | F | Y | 80 | KG | 2023-03-20 | null | CN | SE | SE | 2023Q1 | 27 | Female | Consumer | Expedited | 80 |
230,014,131 | 23,001,413 | 1 | I | null | 20,230,712 | 2023-09-28 | 2023-09-28 | EXP | null | US-ENDO-CASE-0023085 | ENDO | null | null | null | null | M | Y | null | null | 2023-09-28 | null | CN | US | null | 2023Q3 | null | Male | Consumer | Expedited | null |
228,880,421 | 22,888,042 | 1 | I | null | 20,230,828 | 2023-08-31 | 2023-08-31 | EXP | null | US-UCBSA-2023042735 | UCB | Rosenfeld WE, Ferrari L, Kerr WT, Sperling MR. Sudden unexpected death in epilepsy during cenobamate clinical development. Epilepsia. 2023;64(8):2108-2115 | 27 | YR | null | M | Y | null | null | 2023-08-31 | null | HP | US | US | 2023Q3 | 27 | Male | Health professional | Expedited | null |
216,131,183 | 21,613,118 | 3 | F | 20,220,101 | 20,230,117 | 2022-11-18 | 2023-01-25 | PER | null | NVSC2022US259748 | NOVARTIS | null | null | null | null | M | Y | null | null | 2023-01-25 | null | CN | US | US | 2023Q1 | null | Male | Consumer | Periodic | null |
192,553,712 | 19,255,371 | 2 | F | 20,201,228 | 20,210,211 | 2021-05-13 | 2023-05-30 | PER | null | US-UCBSA-2021004008 | UCB | null | 43 | YR | null | M | Y | 72.5 | KG | 2023-05-30 | null | HP | US | US | 2023Q2 | 43 | Male | Health professional | Periodic | 72.5 |
231,962,311 | 23,196,231 | 1 | I | null | 20,231,108 | 2023-11-17 | 2023-11-17 | EXP | null | GB-BAUSCH-BL-2023-016779 | BAUSCH AND LOMB | Patel H, Osman N, Gaoatswe G. Hyperosmolar hyperglycaemic state secondary to steroid use in a neuroloncology patient. British Journal of Diabetes. 2023 JUN 01;23 (1):12. doi:10.15277/bjd.2023.407 | 70 | YR | null | M | Y | null | null | 2023-11-17 | null | HP | GB | GB | 2023Q4 | 70 | Male | Health professional | Expedited | null |
219,953,641 | 21,995,364 | 1 | I | null | null | 2023-02-14 | 2023-02-14 | DIR | 648562 | null | FDA-CTU | null | null | null | null | UNK | N | null | null | 2023-02-14 | null | CN | US | null | 2023Q1 | null | Unknown | Consumer | Direct | null |
219,137,972 | 21,913,797 | 2 | F | null | 20,230,207 | 2023-01-25 | 2023-02-13 | EXP | null | GB-ROCHE-3272003 | ROCHE | Md Yusof M, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital E and Emery P. Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes during Rituximab Therapy in Autoimmune Rheumatic Diseases [Abstract number: 0783]. DOI: 10.1002/art.42355. Arthritis and Rheumatology. 2022 Sep;74 (SUPPLEMENT 9):1559-60. | null | null | A | F | Y | null | null | 2023-02-13 | null | HP | GB | null | 2023Q1 | null | Female | Health professional | Expedited | null |
222,979,861 | 22,297,986 | 1 | I | null | 20,230,505 | 2023-05-09 | 2023-05-09 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-065331 | BRISTOL MYERS SQUIBB | null | 85 | YR | E | M | Y | null | null | 2023-05-09 | null | CN | US | US | 2023Q2 | 85 | Male | Consumer | Periodic | null |
222,675,321 | 22,267,532 | 1 | I | null | 20,230,424 | 2023-04-29 | 2023-04-29 | PER | null | US-PFIZER INC-PV202300074743 | PFIZER | null | 25 | YR | null | F | Y | 79.38 | KG | 2023-04-29 | null | CN | US | US | 2023Q2 | 25 | Female | Consumer | Periodic | 79.4 |
223,493,276 | 22,349,327 | 6 | F | 20,230,226 | 20,231,121 | 2023-05-22 | 2023-11-28 | EXP | null | NVSC2023GT050013 | NOVARTIS | null | 37 | YR | null | F | Y | null | null | 2023-11-28 | null | CN | GT | GT | 2023Q4 | 37 | Female | Consumer | Expedited | null |
228,414,281 | 22,841,428 | 1 | I | null | 20,230,816 | 2023-08-20 | 2023-08-20 | EXP | null | DE-BIOGEN-2023BI01221965 | BIOGEN | null | null | null | null | F | Y | 60 | KG | 2023-08-20 | null | CN | DE | DE | 2023Q3 | null | Female | Consumer | Expedited | 60 |
222,940,801 | 22,294,080 | 1 | I | null | 20,230,428 | 2023-05-08 | 2023-05-08 | 30DAY | null | US-VIIV HEALTHCARE LIMITED-US2023AMR063312 | VIIV | null | null | null | null | M | Y | null | null | 2023-05-08 | null | MD | US | US | 2023Q2 | null | Male | Physician | 30DAY | null |
218,207,532 | 21,820,753 | 2 | F | null | 20,230,120 | 2023-01-05 | 2023-01-26 | EXP | null | US-BIOGEN-2022BI01177997 | BIOGEN | null | null | null | null | F | Y | null | null | 2023-01-26 | null | HP | US | US | 2023Q1 | null | Female | Health professional | Expedited | null |
190,212,672 | 19,021,267 | 2 | F | null | 20,230,906 | 2021-03-17 | 2023-09-08 | EXP | null | IN-PURDUE-USA-2021-0234117 | PURDUE | Bhat I, Arya VK, Mandal V, Jayant A, Dutta V, Rana SS.. Postoperative hemodynamics after high spinal block with or without intrathecal morphine in cardiac surgical patients: a randomized-controlled trial. Can J Anesth/J Can Anesth.. 2021 | null | null | A | null | Y | null | null | 2023-09-08 | null | MD | IN | IN | 2023Q3 | null | Unknown | Physician | Expedited | null |
223,125,421 | 22,312,542 | 1 | I | null | 20,230,503 | 2023-05-12 | 2023-05-12 | PER | null | US-JNJFOC-20230525256 | JOHNSON AND JOHNSON | null | null | null | null | M | Y | null | null | 2023-05-12 | null | LW | US | US | 2023Q2 | null | Male | Lawyer | Periodic | null |
226,771,911 | 22,677,191 | 1 | I | null | 20,230,626 | 2023-07-06 | 2023-07-06 | EXP | null | JP-ELI_LILLY_AND_COMPANY-JP202306016292 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 2023-07-06 | null | CN | JP | JP | 2023Q3 | null | Female | Consumer | Expedited | null |
220,337,351 | 22,033,735 | 1 | I | null | 20,230,214 | 2023-02-24 | 2023-02-24 | EXP | null | FR-Accord-301204 | ACCORD | Feliu C, Konecki C, Cazaubon Y, Binet L, Vautier D, Fouley A, et al. Development and Validation of a Non-Targeted Screening Method for Most Psychoactive, Analgesic, Anaesthetic, Anti-Diabetic, Anti-Coagulant and Anti-Hypertensive Drugs in Human Whole Blood and Plasma Using High-Resolution Mass Spectrometry. Pharmaceuti... | 71 | YR | E | F | Y | null | null | 2023-02-24 | null | PH | FR | FR | 2023Q1 | 71 | Female | Pharmacist | Expedited | null |
208,789,605 | 20,878,960 | 5 | F | 20,200,406 | 20,231,113 | 2022-05-26 | 2023-11-18 | EXP | null | US-TAKEDA-US202012805 | TAKEDA | null | 82 | YR | null | M | Y | 75 | KG | 2023-11-18 | null | MD | US | US | 2023Q4 | 82 | Male | Physician | Expedited | 75 |
231,084,411 | 23,108,441 | 1 | I | 20,230,921 | 20,231,019 | 2023-10-26 | 2023-10-26 | EXP | FR-AFSSAPS-CN2023000946 | FR-ROCHE-3442508 | ROCHE | null | 49 | YR | null | F | Y | null | null | 2023-10-26 | null | MD | FR | FR | 2023Q4 | 49 | Female | Physician | Expedited | null |
221,081,131 | 22,108,113 | 1 | I | null | 20,230,314 | 2023-03-17 | 2023-03-17 | PER | null | US-SA-2023SA083915 | SANOFI AVENTIS | null | null | null | A | M | Y | null | null | 2023-03-17 | null | HP | US | US | 2023Q1 | null | Male | Health professional | Periodic | null |
226,174,501 | 22,617,450 | 1 | I | null | 20,220,525 | 2023-06-20 | 2023-06-20 | PER | null | US-PFM-2022-04667 | PIERRE FABRE MEDICAMENT | null | null | null | null | F | Y | 7.256 | KG | 2023-06-20 | null | HP | US | US | 2023Q2 | null | Female | Health professional | Periodic | 7.3 |
226,825,331 | 22,682,533 | 1 | I | null | 20,230,630 | 2023-07-07 | 2023-07-07 | EXP | null | GB-GSK-GB2021GSK057394 | GLAXOSMITHKLINE | Monaghan M, Loh C, Jones S, Oware A, Urankar K, Roderick M et al.. Inflammatory Myositis Secondary to Anti-Retroviral Therapy in a Child; Case Report and Review of the Literature. Journal of neuromuscular diseases. 2021;8:1089-1095 | null | null | null | null | Y | null | null | 2023-07-07 | null | HP | GB | GB | 2023Q3 | null | Unknown | Health professional | Expedited | null |
227,699,603 | 22,769,960 | 3 | F | null | 20,231,121 | 2023-08-01 | 2023-12-04 | PER | null | US-LUPIN PHARMACEUTICALS INC.-2023-06306 | LUPIN | null | null | null | null | null | Y | null | null | 2023-12-04 | null | CN | US | US | 2023Q4 | null | Unknown | Consumer | Periodic | null |
233,062,991 | 23,306,299 | 1 | I | 20,230,912 | 20,231,211 | 2023-12-18 | 2023-12-18 | EXP | null | US-ABBVIE-5529161 | ABBVIE | null | 76 | YR | null | M | Y | null | null | 2023-12-18 | null | CN | US | US | 2023Q4 | 76 | Male | Consumer | Expedited | null |
229,657,381 | 22,965,738 | 1 | I | null | 20,230,913 | 2023-09-21 | 2023-09-21 | EXP | null | US-BAYER-2023A131058 | BAYER | Heydinger S.P.; Abdulaal M.R.; Wang A.L.. Retinal neovascularization in the setting of CALR-mutation positive essential thrombocythemia. SAGE Open Medical Case Reports (2023) 11. 2023;11 | 49 | YR | A | F | Y | null | null | 2023-09-21 | null | HP | US | US | 2023Q3 | 49 | Female | Health professional | Expedited | null |
220,527,815 | 22,052,781 | 5 | F | null | 20,230,609 | 2023-03-02 | 2023-06-10 | PER | null | NVSC2023US046271 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-06-10 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
1,510,600,133 | 15,106,001 | 33 | F | 20,180,606 | 20,231,204 | 2018-07-04 | 2023-12-11 | EXP | null | CA-ROCHE-2137686 | ROCHE | null | 34 | YR | null | F | Y | null | null | 2023-12-11 | null | CN | CA | null | 2023Q4 | 34 | Female | Consumer | Expedited | null |
219,603,241 | 21,960,324 | 1 | I | null | 20,230,131 | 2023-02-07 | 2023-02-07 | EXP | null | US-HETERO-HET2023US00211 | HETERO | Lipsyc-Sharf M, Connell NT, Ostrominski JW, Levy BD, Loscalzo J. A Shear Decline. The New England Journal of Medicine.. 2022;387(18):1700-1706 | 59 | YR | null | M | Y | 95 | KG | 2023-02-07 | null | MD | US | US | 2023Q1 | 59 | Male | Physician | Expedited | 95 |
229,367,971 | 22,936,797 | 1 | I | 20,230,101 | 20,230,724 | 2023-09-12 | 2023-09-12 | PER | null | US-KARYOPHARM-2023KPT001647 | KARYOPHARM THERAPEUTICS | null | null | null | null | null | Y | null | null | 2023-09-12 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Periodic | null |
231,230,772 | 23,123,077 | 2 | F | null | 20,231,024 | 2023-10-30 | 2023-11-08 | 30DAY | null | KZ-JNJFOC-20231055480 | JOHNSON AND JOHNSON | null | null | null | null | null | Y | null | null | 2023-11-09 | null | MD | KZ | KZ | 2023Q4 | null | Unknown | Physician | 30DAY | null |
216,564,102 | 21,656,410 | 2 | F | 20,221,113 | 20,221,212 | 2022-11-29 | 2023-01-04 | PER | null | US-AMGEN-USASP2022196919 | AMGEN | null | 65 | YR | E | M | Y | null | null | 2023-01-04 | null | CN | US | US | 2023Q1 | 65 | Male | Consumer | Periodic | null |
223,060,661 | 22,306,066 | 1 | I | 20,230,101 | 20,230,509 | 2023-05-11 | 2023-05-11 | EXP | null | MX-ABBVIE-4760720 | ABBVIE | null | null | null | null | F | Y | 69 | KG | 2023-05-11 | null | CN | MX | MX | 2023Q2 | null | Female | Consumer | Expedited | 69 |
227,099,061 | 22,709,906 | 1 | I | null | 20,230,713 | 2023-07-17 | 2023-07-17 | EXP | null | US-ABBVIE-5327427 | ABBVIE | null | null | null | null | F | Y | null | null | 2023-07-17 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Expedited | null |
145,291,525 | 14,529,152 | 5 | F | null | 20,231,010 | 2018-02-14 | 2023-10-17 | EXP | null | CA-APOTEX-2018AP006371 | APOTEX | null | 18 | YR | null | F | Y | 63 | KG | 2023-10-17 | null | HP | CA | CA | 2023Q4 | 18 | Female | Health professional | Expedited | 63 |
227,218,442 | 22,721,844 | 2 | F | null | 20,230,830 | 2023-07-19 | 2023-09-04 | EXP | null | JP-GILEAD-2023-0636289 | GILEAD | null | 6 | DEC | A | F | Y | null | null | 2023-09-04 | null | MD | JP | JP | 2023Q3 | 60 | Female | Physician | Expedited | null |
207,929,892 | 20,792,989 | 2 | F | null | 20,221,129 | 2022-05-06 | 2023-05-31 | PER | null | US-UCBSA-2021029306 | UCB | null | null | null | null | M | Y | 127.91 | KG | 2023-05-31 | null | HP | US | US | 2023Q2 | null | Male | Health professional | Periodic | 127.9 |
229,742,142 | 22,974,214 | 2 | F | 20,230,101 | 20,231,109 | 2023-09-23 | 2023-11-10 | PER | null | NVSC2023US206105 | NOVARTIS | null | null | null | null | M | Y | null | null | 2023-11-11 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Periodic | null |
192,482,864 | 19,248,286 | 4 | F | 20,210,301 | 20,230,906 | 2021-05-12 | 2023-09-11 | EXP | null | US-PFIZER INC-2021508853 | PFIZER | null | 84 | YR | null | M | Y | 90.72 | KG | 2023-09-11 | null | CN | US | US | 2023Q3 | 84 | Male | Consumer | Expedited | 90.7 |
223,913,661 | 22,391,366 | 1 | I | null | 20,230,526 | 2023-06-01 | 2023-06-01 | EXP | null | JP-EXELIXIS-CABO-23064217 | EXELIXIS | null | 67 | YR | null | M | Y | null | null | 2023-06-01 | null | MD | JP | JP | 2023Q2 | 67 | Male | Physician | Expedited | null |
225,407,363 | 22,540,736 | 3 | F | 20,230,101 | 20,230,801 | 2023-06-09 | 2023-08-04 | EXP | null | US-SA-2023SA176784 | SANOFI AVENTIS | null | 61 | YR | A | F | Y | 54.4 | KG | 2023-08-04 | null | MD | US | US | 2023Q3 | 61 | Female | Physician | Expedited | 54.4 |
222,150,002 | 22,215,000 | 2 | F | null | 20,230,508 | 2023-04-15 | 2023-05-12 | EXP | null | NVSC2023ES082253 | NOVARTIS | null | 45 | YR | null | F | Y | null | null | 2023-05-12 | null | CN | ES | ES | 2023Q2 | 45 | Female | Consumer | Expedited | null |
216,181,443 | 21,618,144 | 3 | F | null | 20,230,421 | 2022-11-19 | 2023-04-26 | PER | null | NVSC2022US260063 | NOVARTIS | null | null | null | null | M | Y | 108.86 | KG | 2023-04-26 | null | CN | US | US | 2023Q2 | null | Male | Consumer | Periodic | 108.9 |
221,755,991 | 22,175,599 | 1 | I | 20,230,307 | 20,230,331 | 2023-04-05 | 2023-04-05 | PER | null | US-EMD Serono-9394119 | EMD SERONO INC | null | 63 | YR | A | F | Y | null | null | 2023-04-05 | null | CN | US | null | 2023Q2 | 63 | Female | Consumer | Periodic | null |
226,538,951 | 22,653,895 | 1 | I | null | 20,230,621 | 2023-06-29 | 2023-06-29 | PER | null | US-SA-2023SA194183 | SANOFI AVENTIS | null | null | null | E | F | Y | null | null | 2023-06-29 | null | MD | US | US | 2023Q2 | null | Female | Physician | Periodic | null |
218,640,911 | 21,864,091 | 1 | I | 20,221,129 | 20,221,214 | 2023-01-16 | 2023-01-16 | PER | null | US-ABBVIE-4238035 | ABBVIE | null | 62 | YR | null | F | Y | null | null | 2023-01-16 | null | CN | US | US | 2023Q1 | 62 | Female | Consumer | Periodic | null |
220,761,241 | 22,076,124 | 1 | I | 20,230,205 | 20,230,228 | 2023-03-09 | 2023-03-09 | EXP | null | SK-GLAXOSMITHKLINE-SKCH2023HLN010218 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-03-09 | null | PH | SK | SK | 2023Q1 | null | Unknown | Pharmacist | Expedited | null |
221,508,561 | 22,150,856 | 1 | I | 20,221,201 | 20,230,323 | 2023-03-29 | 2023-03-29 | PER | null | US-SA-2023SA097226 | SANOFI AVENTIS | null | 73 | YR | E | M | Y | null | null | 2023-03-29 | null | CN | US | US | 2023Q1 | 73 | Male | Consumer | Periodic | null |
233,079,881 | 23,307,988 | 1 | I | null | 20,231,215 | 2023-12-15 | 2023-12-15 | DIR | FDA-CDER-CTU-2023-92168 | null | FDA-CTU | null | 33 | YR | null | M | N | 205 | LBS | 2023-12-15 | N | null | US | null | 2023Q4 | 33 | Male | null | Direct | 93 |
226,950,022 | 22,695,002 | 2 | F | null | 20,230,727 | 2023-07-12 | 2023-07-31 | EXP | null | US-ABBVIE-5306589 | ABBVIE | null | null | null | null | M | Y | null | null | 2023-07-31 | null | MD | US | US | 2023Q3 | null | Male | Physician | Expedited | null |
222,434,071 | 22,243,407 | 1 | I | null | 20,230,414 | 2023-04-24 | 2023-04-24 | EXP | null | US-GSK-US2023055319 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-04-24 | null | MD | US | US | 2023Q2 | null | Unknown | Physician | Expedited | null |
221,467,951 | 22,146,795 | 1 | I | 20,230,320 | 20,230,320 | 2023-03-28 | 2023-03-28 | EXP | null | US-ROCHE-3314828 | ROCHE | null | null | null | null | null | Y | null | null | 2023-03-28 | null | CN | US | null | 2023Q1 | null | Unknown | Consumer | Expedited | null |
222,905,791 | 22,290,579 | 1 | I | null | 20,230,412 | 2023-05-05 | 2023-05-05 | PER | null | US-GALDERMA-US2023005912 | GALDERMA | null | null | null | null | null | Y | null | null | 2023-05-05 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Periodic | null |
228,286,991 | 22,828,699 | 1 | I | 20,220,505 | 20,230,814 | 2023-08-16 | 2023-08-16 | EXP | null | TW-TAKEDA-2023TUS079567 | TAKEDA | null | 64 | YR | null | M | Y | null | null | 2023-08-16 | null | CN | TW | TW | 2023Q3 | 64 | Male | Consumer | Expedited | null |
230,635,421 | 23,063,542 | 1 | I | 20,230,407 | 20,231,010 | 2023-10-13 | 2023-10-13 | EXP | null | US-AstraZeneca-2023A230731 | ASTRAZENECA | null | 22,874 | DY | null | null | Y | null | null | 2023-10-13 | null | HP | US | null | 2023Q4 | 62.63 | Unknown | Health professional | Expedited | null |
218,589,291 | 21,858,929 | 1 | I | null | 20,230,111 | 2023-01-13 | 2023-01-13 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-005392 | BRISTOL MYERS SQUIBB | null | 74 | YR | E | F | Y | null | null | 2023-01-13 | null | PH | US | US | 2023Q1 | 74 | Female | Pharmacist | Expedited | null |
225,959,001 | 22,595,900 | 1 | I | null | 20,230,607 | 2023-06-13 | 2023-06-13 | EXP | null | CL-MYLANLABS-2023M1061753 | MYLAN | null | null | null | null | M | Y | null | null | 2023-06-13 | null | PH | CL | CL | 2023Q2 | null | Male | Pharmacist | Expedited | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.